Form 4: CME Group Counsel Sells Shares Under 10b5-1 Plan

Jonathan L. Marcus, CME Group's Senior Managing Director and General Counsel, sold 392 shares of Class A Common Stock for $262 per share pursuant to a pre-arranged Rule 10b5-1 plan.

Summary

• Jonathan L. Marcus, Sr MD General Counsel of CME Group Inc. (CME), reported a transaction involving the company's securities.
• Marcus disposed of 392 shares of CME Group Class A Common Stock.
• The transaction occurred on September 18, 2025, at a price of $262 per share.
• This sale was executed under a Rule 10b5-1 plan, which was adopted on February 18, 2025.
• Following this transaction, Marcus beneficially owns 7,851 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale conducted under a pre-arranged Rule 10b5-1 plan, which mitigates any negative sentiment typically associated with insider selling. It does not indicate new positive or negative information about the company.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a scheduled sale for personal financial planning rather than a reaction to new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct equity stake of a senior executive in the company.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Comparison to Industry Standards

• This filing is a standard insider transaction report and does not contain information that allows for comparison to global benchmarks or specific comparable companies or projects.

Stakeholder Impact

• Shareholders may note the reduction in direct equity ownership by a senior executive, though the pre-arranged nature of the sale under a 10b5-1 plan suggests it is for personal financial planning rather than a reflection of company performance.

Key Dates

Recommendation

This Form 4 reports a relatively small, pre-scheduled sale of shares by a senior executive under a Rule 10b5-1 plan. Such transactions are typically for personal financial management and do not usually signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

CME Group, CME, Insider Trading, Form 4, Jonathan L. Marcus, Stock Sale, 10b5-1 Plan, Officer Transaction, Equity Disposition